Clinical Trial Update: Intravitreal Avastin in Proliferative Retinopathies [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravitreal bevacizumab (Avastin) for proliferative retinopathies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Neovascularization

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Sponsor: Ophthalmological Association Edelweiss | Conditions: Retinal Neovascularization | Phase 2 | Status: COMPLETED